Signature Diagnostics will establish corporate partnerships with the aim of discovering, validating, developing, and licensing predictive
diagnostics in oncology. All our products will be provided to corporate partners under partnership agreements tailored to the partner’s needs and integrated into the partner’s clinical development process. Collaboration periods will be between two and five years depending on the stage of clinical development of the experimental drug and the specific tumor indication.

Collaborations may focus on the discovery and validation of specific drug response signatures for a particular cancer drug, or a drug combination. Ideally, corporate collaboration should start well in advance or at the beginning of a phase II clinical trial. Collaborations can also be initiated when a new cancer drug or drug combination has already successfully completed clinical phase II and is about to enter phase III. Signature Diagnostics will consider the out-licensing of specific drug response signatures to the corporate partner. Transfer points could be completion of discovery, validation, development of commercial assay, or regulatory approval of the drug response signature diagnostics.

In addition, the company will consider the out-licensing of the complete tumor profile/drug response database generated during the collaboration with the pharmaceutical partner. This would allow the partner to use the database for its own in-house target discovery and validation activities.